# Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

> **NCT06035016** · — · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 300 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Early-stage Breast Cancer

## Interventions

- **DRUG:** pyrotinib combined with Capecitabine
- **DRUG:** treatment of physician's choice

## Key facts

- **NCT ID:** NCT06035016
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035016, "Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06035016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*